Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aprea Therapeutics, Inc.APRE · Entity 7948 | Director | June 16, 2026 | June 17, 2026 |
| MERRIMACK PHARMACEUTICALS INCMACK · Entity 95770 | Director · President and CEO | May 08, 2019 | May 10, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aprea Therapeutics, Inc.
Report date June 16, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,254 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 3,135 · Balance 6,254 F1: These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2036-06-16 | Direct | 12,555 |
Reported balance
After 2026-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-16 · Grant · Acquired 12,555 · Balance 12,555 F2: The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
F2: The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
MERRIMACK PHARMACEUTICALS INC
Report date May 08, 2019 · Filed May 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.74 · Expires 2028-02-14 | Direct | 200,000 |
Reported balance
After 2019-05-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-08 · Other · Disposed 25,000 · Balance 200,000 F1: An option to purchase 225,000 shares was originally granted to the Reporting Person on February 15, 2018. 25,000 shares underlying this option were rescinded on May 8, 2019. F2: This option vested as to 1/12th of the total number of shares originally granted on 5/15/18 and an additional 1/12th of the total number of shares originally granted at the end of each successive three month period thereafter until 2/15/21. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.15 · Expires 2028-12-10 | Direct | 0 |
Reported balance
After 2019-05-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-05-08 · Other · Disposed 225,000 · Balance 0 F3: An option to purchase 225,000 shares was originally granted to the Reporting Person on December 11, 2018. This option was rescinded in full on May 8, 2019. F4: The original vesting schedule for this option was 1/12th of the total number of shares granted on 3/11/19 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until 12/11/21. |
Filing footnotes · ownership attribution and instrument terms
F1: An option to purchase 225,000 shares was originally granted to the Reporting Person on February 15, 2018. 25,000 shares underlying this option were rescinded on May 8, 2019.
F2: This option vested as to 1/12th of the total number of shares originally granted on 5/15/18 and an additional 1/12th of the total number of shares originally granted at the end of each successive three month period thereafter until 2/15/21.
F3: An option to purchase 225,000 shares was originally granted to the Reporting Person on December 11, 2018. This option was rescinded in full on May 8, 2019.
F4: The original vesting schedule for this option was 1/12th of the total number of shares granted on 3/11/19 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until 12/11/21.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
KINETA, INC./DE
Report date June 30, 2025 · Filed July 02, 2025
Section 16 reporting ended · disclosed 2025-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-06-30 transaction · row 1
1 source rowRow 1 · 2025-06-30 · Disposition to issuer · Disposed 101,891 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F3: At the effective time of the First Merger (the "Effective Time"), each one (1) issued and outstanding share of Kineta's common stock, par value $0.001 per share ("Kineta Common Stock"), was cancelled and converted into the right to receive 0.185298 share of common stock of TuHURA, par value $0.001 per share ("TuHURA Common Stock"). Also pursuant to the Merger Agreement, each one (1) share of Kineta Common Stock is also entitled to (i) its pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the Mergers, subject to adjustment for losses incurred or accrued during the six month period from the closing of the Mergers, and (ii) the right to its pro rata share of cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.28 | Direct | 0 |
Reported balance
After 2025-06-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-30 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F4: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.28 | Direct | 0 |
Reported balance
After 2025-06-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-06-30 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F4: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement").
F2: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA.
F3: At the effective time of the First Merger (the "Effective Time"), each one (1) issued and outstanding share of Kineta's common stock, par value $0.001 per share ("Kineta Common Stock"), was cancelled and converted into the right to receive 0.185298 share of common stock of TuHURA, par value $0.001 per share ("TuHURA Common Stock"). Also pursuant to the Merger Agreement, each one (1) share of Kineta Common Stock is also entitled to (i) its pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the Mergers, subject to adjustment for losses incurred or accrued during the six month period from the closing of the Mergers, and (ii) the right to its pro rata share of cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets.
F4: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 17, 2026 23:06 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Options (Right to Buy) · Derivative | 12,555 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001104659-26-075283 · tm2618211-6_4seq1.xml · derivative · entry 2 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,555 Underlying: Common Stock · 12,555 shares Expires 2036-06-16 F2 · derivative.exercise_date: The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 23:06 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 3,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-075283 · tm2618211-6_4seq1.xml · nonDerivative · entry 1 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,254 F1 · shares: These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 20:15 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Warrant · Derivative | 123,915 | Not disclosed Strike: $0.68 | Not disclosed |
DisclosureSEC source: 0001104659-26-038518 · tm2610878-1_4seq1.xml · derivative · entry 2 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,915 Underlying: Common Stock · 123,915 shares Expires not disclosed F1 · security: On March 30, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on March 31, 2026, (i) pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 123,915 shares of the Issuer's common stock ("Shares") at a purchase price of $0.808, less the $0.001 exercise price, per Pre-Funded Warrant and (ii) accompanying common warrants ("Common Warrants") to purchase up to an aggregate of 123,915 Shares. F1 · price: On March 30, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on March 31, 2026, (i) pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 123,915 shares of the Issuer's common stock ("Shares") at a purchase price of $0.808, less the $0.001 exercise price, per Pre-Funded Warrant and (ii) accompanying common warrants ("Common Warrants") to purchase up to an aggregate of 123,915 Shares. F3 · derivative.expiration_date: The Common Warrants are immediately exercisable, subject to the Beneficial Ownership Limitation. The Common Warrants will expire on the earlier of (ii) December 31, 2029, and (ii) 30 calendars days after the date upon which the Pre-Funded Warrant is exercised, proportional to the amount of such exercise. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 20:15 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchasePre-Funded Warrant · Derivative | 123,915 | $0.81 Strike: $0.00 | $99,999.41 |
DisclosureSEC source: 0001104659-26-038518 · tm2610878-1_4seq1.xml · derivative · entry 1 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,915 Underlying: Common Stock · 123,915 shares Expires not disclosed F1 · security: On March 30, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on March 31, 2026, (i) pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 123,915 shares of the Issuer's common stock ("Shares") at a purchase price of $0.808, less the $0.001 exercise price, per Pre-Funded Warrant and (ii) accompanying common warrants ("Common Warrants") to purchase up to an aggregate of 123,915 Shares. F2 · derivative.expiration_date: The Pre-Funded Warrants are immediately exercisable at any time after the date of issuance. Pursuant to the terms of the Pre-Funded Warrants, the Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise (the "Beneficial Ownership Limitation") Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 16:26 UTC | KINETA, INC./DE KANT · Entity 77778 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0000950170-25-093015 · ownership.xml · derivative · entry 3 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2 · kind: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F4 · derivative.exercise_date: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration. F4 · derivative.expiration_date: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 16:26 UTC | KINETA, INC./DE KANT · Entity 77778 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0000950170-25-093015 · ownership.xml · derivative · entry 2 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2 · kind: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F4 · derivative.exercise_date: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration. F4 · derivative.expiration_date: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 16:26 UTC | KINETA, INC./DE KANT · Entity 77778 | Disposition to issuerCommon Stock | 101,891 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-093015 · ownership.xml · nonDerivative · entry 1 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2 · kind: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F3 · price: At the effective time of the First Merger (the "Effective Time"), each one (1) issued and outstanding share of Kineta's common stock, par value $0.001 per share ("Kineta Common Stock"), was cancelled and converted into the right to receive 0.185298 share of common stock of TuHURA, par value $0.001 per share ("TuHURA Common Stock"). Also pursuant to the Merger Agreement, each one (1) share of Kineta Common Stock is also entitled to (i) its pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the Mergers, subject to adjustment for losses incurred or accrued during the six month period from the closing of the Mergers, and (ii) the right to its pro rata share of cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets. Read SEC document |
| June 25, 2025 Filed Jun 25, 2025 21:54 UTC | KINETA, INC./DE KANT · Entity 77778 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-090144 · ownership.xml · nonDerivative · entry 3 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,891 Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:54 UTC | KINETA, INC./DE KANT · Entity 77778 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000950170-25-090144 · ownership.xml · derivative · entry 4 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2034-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Pursuant to the terms of (i) the Optionholder Treatment Agreement, dated June 16, 2025, by and between Kineta, Inc. (the "Company") and the Reporting Person, and (ii) the Agreement and Plan of Merger, dated as of December 11, 2024, by and among the Company, TuHURA Biosciences, Inc., a Nevada corporation ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of TuHURA, Hura Merger Sub II, a Delaware limited liability company and a wholly owned subsidiary of TuHURA, and Craig Philips, as representative of the stockholders of the Company, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025, as approved by the Company's stockholders at the Special Meeting of Stockholders held on June 23, 2025, the options granted to the Reporting Person under the 2022 Equity Incentive Plan became fully vested on June 23, 2025. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:54 UTC | KINETA, INC./DE KANT · Entity 77778 | Tax withholdingCommon Stock | 4,706 | $0.26 | $1,223.56 |
DisclosureSEC source: 0000950170-25-090144 · ownership.xml · nonDerivative · entry 2 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,891 Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:54 UTC | KINETA, INC./DE KANT · Entity 77778 | Exercise / conversionCommon Stock | 12,500 | $0.61 | $7,637.50 |
DisclosureSEC source: 0000950170-25-090144 · ownership.xml · nonDerivative · entry 1 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:06 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Options (Right to Buy) · Derivative | 4,185 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001104659-25-057821 · tm2517366-7_4seq1.xml · derivative · entry 2 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,185 Underlying: Common Stock · 4,185 shares Expires 2035-06-05 F2 · derivative.exercise_date: The option vests in full on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:06 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 1,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-057821 · tm2517366-7_4seq1.xml · nonDerivative · entry 1 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,119 F1 · shares: These shares represent restricted stock units which were granted on June 5, 2025, and which will vest and be settled in common stock on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| September 04, 2024 Filed Sep 5, 2024 16:21 UTC | KINETA, INC./DE KA · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000950170-24-104023 · ownership.xml · derivative · entry 1 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-09-03 F1 · derivative.exercise_date: The stock option will vest in equal quarterly installments over one year following June 21, 2024, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:18 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Options (Right to Buy) · Derivative | 4,185 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001104659-24-073943 · tm2417666-4_4seq1.xml · derivative · entry 2 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,185 Underlying: Common Stock · 4,185 shares Expires 2034-06-20 F2 · derivative.exercise_date: The option vests in full on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:18 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 1,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-073943 · tm2417666-4_4seq1.xml · nonDerivative · entry 1 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,074 F1 · shares: These shares represent restricted stock units which were granted on June 20, 2024, and which will vest and be settled in common stock on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 01:50 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Options (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001104659-23-095018 · tm2324788-5_4seq1.xml · derivative · entry 2 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2033-08-23 F2 · derivative.exercise_date: The option vests in full on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 01:50 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-095018 · tm2324788-5_4seq1.xml · nonDerivative · entry 1 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,029 F1 · shares: These shares represent restricted stock units which were granted on August 23, 2023, and which will vest and be settled in common stock on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 16:11 UTC | KINETA, INC./DE KA · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0001209191-23-024300 · doc4.xml · derivative · entry 2 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-04-11 F2 · derivative.exercise_date: The stock option will vest as to 1/12 of the total number of shares on July 7, 2023 and each monthly anniversary thereafter, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 16:11 UTC | KINETA, INC./DE KA · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0001209191-23-024300 · doc4.xml · derivative · entry 1 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-04-11 F1 · derivative.exercise_date: The stock option vested and continues to vest as to 1/36 of the total number of shares on February 1, 2023 and on each monthly anniversary thereafter, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 20:59 UTC | KINETA, INC./DE KA · Entity 77778 | Tax withholdingCommon Stock | 1,931 | $1.86 | $3,591.66 |
DisclosureSEC source: 0001209191-22-062282 · doc4.xml · nonDerivative · entry 1 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,097 F1 · kind: Shares withheld by the Company in payment of the withholding tax liability incurred upon settlement of restricted stock units previously awarded. The amount of shares withheld is based on the closing sale price on December 16, 2022. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 16:56 UTC | KINETA, INC./DE YMTX · Entity 77778 | SaleCommon Stock | 10,890 | $1.69 | $18,418.26 |
DisclosureSEC source: 0000899243-22-037790 · doc4.xml · nonDerivative · entry 1 Peters Richard · CIK 0001697628 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,028 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of shares of restricted stock granted to the Reporting Person. This sale is mandated by the Issuer, Yumanity Therapeutics, Inc., to satisfy tax withholding obligations by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 21:05 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 29,575 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0001104659-22-084770 · tm2222147-8_4seq1.xml · derivative · entry 2 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,575 Underlying: Common Stock · 29,575 shares Expires 2032-07-28 F2 · derivative.exercise_date: The option vests in full on July 28, 2023, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 21:05 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 5,995 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-084770 · tm2222147-8_4seq1.xml · nonDerivative · entry 1 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,605 F1 · shares: These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock on July 28, 2023, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 16:54 UTC | KINETA, INC./DE YMTX · Entity 77778 | SaleCommon Stock | 4,584 | $1.85 | $8,476.27 |
DisclosureSEC source: 0000899243-22-025399 · doc4.xml · nonDerivative · entry 1 Peters Richard · CIK 0001697628 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,918 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units granted to the Reporting Person. This sale is mandated by the Issuer, Yumanity Therapeutics, Inc., to satisfy tax withholding obligations by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| June 03, 2022 Filed Jun 6, 2022 21:45 UTC | KINETA, INC./DE YMTX · Entity 77778 | SaleCommon Stock | 10,206 | $1.19 | $12,192.09 |
DisclosureSEC source: 0000899243-22-021283 · doc4.xml · nonDerivative · entry 1 Peters Richard · CIK 0001697628 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,502 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of shares of restricted stock granted to the Reporting Person. This sale is mandated by the Issuer, Yumanity Therapeutics, Inc., to satisfy tax withholding obligations by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.14 to $1.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| March 28, 2022 Filed Mar 30, 2022 16:05 UTC | KINETA, INC./DE YMTX · Entity 77778 | SaleCommon Stock | 10,715 | $1.85 | $19,774.53 |
DisclosureSEC source: 0000899243-22-012782 · doc4.xml · nonDerivative · entry 1 Peters Richard · CIK 0001697628 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,708 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 25, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 16:15 UTC | KINETA, INC./DE YMTX · Entity 77778 | GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-046760 · doc4.xml · nonDerivative · entry 1 Peters Richard · CIK 0001697628 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,423 F1 · shares: Restricted stock award granted under the Yumanity Therapeutics, Inc. Amended and Restated 2018 Stock Option and Grant Plan. Fifty percent of the shares subject to the award will vest six months after the grant date and fifty percent will vest twelve months after the grant date, provided that the award recipient continues to have a service relationship with the Company at such time. Read SEC document |
| July 06, 2021 Filed Jul 7, 2021 16:44 UTC | KINETA, INC./DE YMTX · Entity 77778 | Tax withholdingCommon Stock | 79 | $10.79 | $852.41 |
DisclosureSEC source: 0000899243-21-027794 · doc4.xml · nonDerivative · entry 2 Peters Richard · CIK 0001697628 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,423 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs granted to the Reporting Person. This sale is mandated by the Issuer, Yumanity Therapeutics, Inc., to satisfy tax withholding obligations by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 16:44 UTC | KINETA, INC./DE YMTX · Entity 77778 | Tax withholdingCommon Stock | 4,441 | $11.11 | $49,339.51 |
DisclosureSEC source: 0000899243-21-027794 · doc4.xml · nonDerivative · entry 1 Peters Richard · CIK 0001697628 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,502 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs granted to the Reporting Person. This sale is mandated by the Issuer, Yumanity Therapeutics, Inc., to satisfy tax withholding obligations by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.104182 to $11.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 23:02 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (Right to Buy) · Derivative | 22,750 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001567619-21-012873 · doc1.xml · derivative · entry 2 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,750 Underlying: Common Stock · 22,750 shares Expires 2031-06-30 F2 · derivative.exercise_date: The option vests in full on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 23:02 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 4,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-012873 · doc1.xml · nonDerivative · entry 1 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,610 F1 · shares: These shares represent restricted stock units which were granted on June 30, 2021, and which will vest and be settled in common stock on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 18:42 UTC | KINETA, INC./DE YMTX · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 60,944 | $0.00 Strike: $17.89 | $0.00 |
DisclosureSEC source: 0000899243-21-004749 · doc4.xml · derivative · entry 3 Peters Richard · CIK 0001697628 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,944 Underlying: Common Stock · 60,944 shares Expires 2031-01-31 F3 · derivative.exercise_date: This option shall vest and become exercisable in 48 equal monthly installments over four years following July 1, 2020. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 18:42 UTC | KINETA, INC./DE YMTX · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $17.89 | $0.00 |
DisclosureSEC source: 0000899243-21-004749 · doc4.xml · derivative · entry 2 Peters Richard · CIK 0001697628 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2031-01-31 F2 · derivative.exercise_date: This option shall vest and become exercisable in 48 equal monthly installments over four years following the Grant Date. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 18:42 UTC | KINETA, INC./DE YMTX · Entity 77778 | GrantCommon Stock | 60,943 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004749 · doc4.xml · nonDerivative · entry 1 Peters Richard · CIK 0001697628 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,943 F1 · kind: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in four equal annual installments over four years following July 1, 2020. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 19:14 UTC | KINETA, INC./DE YMTX · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 235,237 | Not disclosed Strike: $8.16 | Not disclosed |
DisclosureSEC source: 0000899243-20-035276 · doc4.xml · derivative · entry 1 Peters Richard · CIK 0001697628 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,237 Underlying: Common Stock · 235,237 shares Expires 2029-09-08 F1 · date: On August 22, 2020, the Issuer (formerly known as Proteostasis Therapeutics, Inc.) entered into an Agreement and Plan of Merger and Reorganization, as amended on November 6, 2020, with Pangolin Merger Sub, Inc. ("Merger Sub"), Yumanity, Inc. (formerly known as Yumanity Therapeutics, Inc.) and Yumanity Holdings, LLC ("Holdings"). On December 22, 2020, Merger Sub was merged with and into Yumanity, Inc., with Yumanity, Inc. surviving as a wholly-owned subsidiary of the Issuer (the "Merger"). Immediately prior to the consummation of the Merger, Holdings was merged with and into Yumanity, Inc., with Yumanity, Inc. as the surviving entity. F3 · price: Received in the Merger in exchange for a stock option to acquire 1,115,708 shares of Yumanity, Inc. common stock for $1.72 per share. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on July 10, 2020. The remaining 75% vest in equal monthly installments over the subsequent three years. Read SEC document |
| June 26, 2020 Filed Jun 29, 2020 22:04 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 7,000 | $0.00 Strike: $38.32 | $0.00 |
DisclosureSEC source: 0000905148-20-000732 · form4.xml · derivative · entry 1 Peters Richard · CIK 0001697628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2030-06-26 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 26, 2021 subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| May 08, 2019 Filed May 10, 2019 07:39 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | OtherStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0001209191-19-028674 · doc4.xml · derivative · entry 2 Peters Richard · CIK 0001697628 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2028-12-10 F3 · kind: An option to purchase 225,000 shares was originally granted to the Reporting Person on December 11, 2018. This option was rescinded in full on May 8, 2019. F4 · derivative.exercise_date: The original vesting schedule for this option was 1/12th of the total number of shares granted on 3/11/19 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until 12/11/21. Read SEC document |
| May 08, 2019 Filed May 10, 2019 07:39 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | OtherStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $10.74 | $0.00 |
DisclosureSEC source: 0001209191-19-028674 · doc4.xml · derivative · entry 1 Peters Richard · CIK 0001697628 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 25,000 shares Expires 2028-02-14 F1 · kind: An option to purchase 225,000 shares was originally granted to the Reporting Person on February 15, 2018. 25,000 shares underlying this option were rescinded on May 8, 2019. F2 · derivative.exercise_date: This option vested as to 1/12th of the total number of shares originally granted on 5/15/18 and an additional 1/12th of the total number of shares originally granted at the end of each successive three month period thereafter until 2/15/21. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 16:18 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0001209191-18-062438 · doc4.xml · derivative · entry 1 Peters Richard · CIK 0001697628 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2028-12-10 F1 · derivative.exercise_date: This option vests as to 1/12th of the total number of shares granted on 3/11/19 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until 12/11/21. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 16:09 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $10.74 | $0.00 |
DisclosureSEC source: 0001209191-18-010816 · doc4.xml · derivative · entry 1 Peters Richard · CIK 0001697628 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2028-02-14 F1 · derivative.exercise_date: This option vests as to 1/12th of the total number of shares granted on 5/15/18 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until 2/15/21. Read SEC document |
| June 06, 2017 Filed Jun 7, 2017 16:45 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | GrantStock Option (right to buy) · Derivative | 2,000,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001209191-17-038322 · doc4.xml · derivative · entry 1 Peters Richard · CIK 0001697628 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2027-06-05 F1 · derivative.exercise_date: This option vests as to 1/4th of the total number of shares granted on 2/6/18 and an additional 1/16th of the total number of shares granted at the end of each successive three month period thereafter until 2/6/21. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.